Melanocortin Receptor Agonists Drug-Drug Interaction Table: A Complete Prescriber Reference

What Is the Melanocortin Receptor Agonist Drug Class?

Melanocortin receptor agonists are peptide or peptide-derived compounds that activate one or more of the five melanocortin receptors (MC1R through MC5R), which are G-protein-coupled receptors expressed in the CNS, skin, adrenal cortex, and peripheral tissues. The FDA has approved two agents in clinical practice: bremelanotide for hypoactive sexual desire disorder (HSDD) and setmelanotide for obesity caused by specific genetic defects in the leptin-melanocortin pathway. Alpha-melanocyte-stimulating hormone (alpha-MSH) is the endogenous ligand for the entire receptor family and served as the pharmacological template for both approved drugs.

Receptor Subtype Selectivity and Clinical Relevance

The five receptor subtypes explain why different agents produce different effects:

• MC1R: expressed in melanocytes and immune cells; activation produces skin pigmentation and anti-inflammatory signaling
• MC3R: expressed in the hypothalamus and limbic system; modulates energy balance and sexual function
• MC4R: expressed densely in the paraventricular nucleus; the dominant receptor for satiety signaling and sexual arousal
• MC5R: expressed in exocrine glands; less clinically characterized

Bremelanotide binds MC1R, MC3R, and MC4R with roughly equal affinity. Setmelanotide is highly selective for MC4R, which accounts for its specific use in genetically defined forms of hyperphagia where the MC4R pathway is disrupted upstream. Cone et al. Established that MC4R knockout mice develop severe obesity, providing the mechanistic basis for setmelanotide's indication.

Approved Indications at a Glance

Bremelanotide carries FDA approval for acquired, generalized HSDD in premenopausal women, as documented in the FDA prescribing label (NDA 210557). Setmelanotide is approved for chronic weight management in adults and pediatric patients aged 6 years and older with obesity caused by POMC deficiency, PCSK1 deficiency, or leptin receptor (LEPR) deficiency, per NDA 213793. Both agents are subcutaneous injectables with no oral formulations currently approved.

Bremelanotide (Vyleesi): Drug-Drug Interaction Profile

Bremelanotide's interaction profile is driven by two pharmacological effects: a transient increase in blood pressure peaking at approximately 1 hour post-dose, and slowing of gastric motility that delays oral drug absorption. It is not metabolized through CYP450 enzymes and does not inhibit or induce them at clinical doses, which limits the number of pharmacokinetic interactions but does not eliminate clinically meaningful pharmacodynamic ones.

Cardiovascular and Blood-Pressure Interactions

The FDA label for bremelanotide reports a mean peak systolic blood pressure increase of approximately 6 mmHg and a mean peak diastolic increase of approximately 3 mmHg, occurring within 60 minutes of injection and resolving within 12 hours in most patients. This effect creates two distinct interaction categories:

Antihypertensives and vasodilators: Patients on amlodipine, lisinopril, losartan, metoprolol, or other antihypertensive agents may experience attenuated drug effect during the bremelanotide pressor window, then relative hypotension as blood pressure falls back to baseline while antihypertensives remain active. Monitoring blood pressure before and 2 to 4 hours after dosing is appropriate in this population.

Nitrates and PDE5 inhibitors: The combination of bremelanotide with nitrates or phosphodiesterase-5 inhibitors (sildenafil, tadalafil, vardenafil) has not been studied in a powered clinical trial, but the opposing hemodynamic effects (bremelanotide raises BP; nitrates and PDE5 inhibitors lower it) introduce unpredictable cardiovascular risk. The American Heart Association sexual activity guidelines advise caution when combining vasoactive drugs in patients with any cardiac history.

Oral Drug Absorption Interactions

Bremelanotide slows gastric emptying, which may reduce the rate and extent of absorption of orally administered drugs taken within 1 hour of injection. The FDA label specifically flags this for drugs with narrow therapeutic windows. Clinically relevant examples include:

| Oral Drug Affected | Mechanism | Clinical Recommendation | |---|---|---| | Naltrexone (oral) | Delayed gastric emptying reduces Cmax | Administer naltrexone at least 1 hour before bremelanotide | | Levothyroxine | Absorption window sensitivity | Separate administration by at least 1 hour | | Warfarin | Delayed absorption alters anticoagulant timing | Monitor INR closely; consider timing separation | | Oral contraceptives (estrogen/progestin) | Absorption may be reduced | Use backup contraception; note bremelanotide is not a contraceptive | | Narrow-TI anticonvulsants (phenytoin, carbamazepine) | Slowed absorption alters serum levels | Counsel patients not to take within 60 minutes of injection |

Nausea-Related Adherence Considerations

Nausea is the most common adverse effect of bremelanotide, reported in 40% of patients in the RECONNECT trials, occasionally leading to vomiting. When a patient vomits within 1 hour of taking an oral medication, the clinical effect is equivalent to a missed dose. This is especially relevant for patients co-prescribed oral diabetes agents, antiepileptics, or antiretrovirals. Pre-treatment with ondansetron 4 mg orally has been used off-label to reduce nausea, though the interaction between ondansetron (a serotonin 5-HT3 antagonist) and bremelanotide's indirect serotonergic signaling has not been formally evaluated.

Setmelanotide (Imcivree): Drug-Drug Interaction Profile

Setmelanotide's interactions differ substantially from bremelanotide's. The primary concerns are CNS-mediated: additive sedation, serotonergic effects, and the need to monitor for spontaneous erections and sexual adverse effects in pediatric patients receiving concomitant medications that also influence sexual function. The FDA label for setmelanotide does not identify formal CYP-mediated drug interactions, as setmelanotide is a peptide degraded by proteolysis rather than hepatic oxidation.

Serotonergic Drug Interactions

Setmelanotide activates MC4R in the dorsal raphe nucleus region and may modestly enhance serotonergic tone. While no published case series documents frank serotonin syndrome with setmelanotide, the pharmacological rationale supports caution when co-prescribing:

• SSRIs (fluoxetine, sertraline, escitalopram)
• SNRIs (duloxetine, venlafaxine)
• Tricyclic antidepressants
• Tramadol
• Triptans (sumatriptan, rizatriptan)
• Linezolid or methylene blue (monoamine oxidase inhibiting agents)

The NIH Serotonin Syndrome guidance recommends using the Hunter Criteria to assess toxicity risk when combining serotonergic agents. Prescribers should review any new serotonergic co-prescription before adding it to a setmelanotide regimen.

CNS Depressant Interactions

Setmelanotide produces somnolence in a subset of patients. In the Phase 3 POMC trial (N=10), setmelanotide produced a mean body weight reduction of 25.6% over 52 weeks, but somnolence was among the adverse events reported. Co-administration with benzodiazepines, opioids, sedating antihistamines, gabapentinoids, or antipsychotics may increase sedation burden. Patients should be counseled specifically about driving safety.

Sexual Adverse Effects and Interacting Medications

Setmelanotide's MC4R agonism can cause spontaneous penile erections and increased sexual desire, particularly in male pediatric patients. This requires careful monitoring when patients also receive:

• Testosterone or anabolic androgens (synergistic pro-erectile signaling)
• PDE5 inhibitors (additive pro-erectile effect)
• Antipsychotics that increase prolactin (potential offsetting effect on desire)

The Endocrine Society 2021 position statement on pharmacotherapy of obesity notes that MC4R agonism-related sexual adverse effects require individualized counseling and that dose reduction is the primary management strategy.

Interaction with Insulin and Antidiabetic Agents

Weight loss from setmelanotide may substantially improve insulin sensitivity over weeks to months. Patients with type 2 diabetes who are also taking insulin, sulfonylureas, or GLP-1 receptor agonists (semaglutide, liraglutide) require proactive dose adjustments as weight falls, because hypoglycemia risk increases as metabolic parameters improve. The American Diabetes Association Standards of Care 2024 recommends pre-emptive reduction of insulin or secretagogue doses when a patient begins a weight-lowering therapy that produces more than 5% body weight reduction.

Comprehensive Drug-Drug Interaction Table

The following table consolidates interactions for both approved melanocortin receptor agonists. Severity ratings follow standard pharmacovigilance conventions: Major (avoid combination or use only with intensive monitoring), Moderate (adjust dose or timing; monitor), Minor (counsel patient; routine monitoring sufficient).

| Interacting Drug / Class | Agent Affected | Interaction Type | Severity | Management | |---|---|---|---|---| | Antihypertensives (any class) | Bremelanotide | Pharmacodynamic: opposing BP effects | Moderate | Monitor BP before and 2-4 hr post-dose | | Nitrates (nitroglycerin, isosorbide) | Bremelanotide | Pharmacodynamic: additive hypotension risk | Major | Avoid concurrent use | | PDE5 inhibitors (sildenafil, tadalafil) | Bremelanotide | Pharmacodynamic: BP unpredictability | Moderate | Counsel on timing; monitor BP | | Naltrexone oral | Bremelanotide | PK: reduced Cmax via delayed gastric emptying | Moderate | Separate by ≥ 1 hour | | Levothyroxine oral | Bremelanotide | PK: delayed absorption | Moderate | Separate by ≥ 1 hour | | Warfarin | Bremelanotide | PK: altered absorption timing | Moderate | Monitor INR; timing separation | | Oral contraceptives | Bremelanotide | PK: reduced absorption | Moderate | Backup contraception recommended | | Narrow-TI anticonvulsants | Bremelanotide | PK: delayed absorption alters steady-state | Major | Avoid co-administration within 60 min | | Antiretrovirals (oral, narrow TI) | Bremelanotide | PK: absorption delay | Moderate | Timing separation; viral load monitoring | | SSRIs / SNRIs | Setmelanotide | Pharmacodynamic: serotonergic additivity | Moderate | Screen using Hunter Criteria; monitor | | Tricyclic antidepressants | Setmelanotide | Pharmacodynamic: serotonergic + sedation | Moderate | Monitor closely | | Tramadol | Setmelanotide | Pharmacodynamic: serotonin + sedation | Moderate | Use lowest effective tramadol dose | | Triptans | Setmelanotide | Pharmacodynamic: serotonergic additivity | Moderate | Limit triptan frequency; monitor | | Linezolid / methylene blue | Setmelanotide | Pharmacodynamic: MAO-inhibition + serotonin | Major | Avoid combination | | Benzodiazepines | Setmelanotide | Pharmacodynamic: additive CNS depression | Moderate | Minimize benzodiazepine dose; warn re: driving | | Opioids | Setmelanotide | Pharmacodynamic: additive sedation | Moderate | Use lowest effective opioid dose | | Gabapentinoids | Setmelanotide | Pharmacodynamic: additive somnolence | Minor | Counsel patient on sedation | | Antipsychotics (dopamine antagonists) | Setmelanotide | Pharmacodynamic: prolactin elevation may offset libido effects | Minor | Monitor for unexpected sexual AEs | | Testosterone / anabolic androgens | Setmelanotide | Pharmacodynamic: synergistic pro-erectile effect | Moderate | Counsel male patients and caregivers | | Insulin / sulfonylureas | Setmelanotide | Pharmacodynamic: hypoglycemia as weight falls | Major | Pre-emptively reduce insulin/SU doses with weight loss ≥ 5% | | GLP-1 receptor agonists | Setmelanotide | Pharmacodynamic: additive weight loss + hypoglycemia risk | Moderate | Monitor glucose; coordinate antidiabetic regimen |

Pharmacokinetics of Both Agents: What Drives the Interaction Profile

Understanding why these agents have a relatively short DDI list requires a firm grasp of their disposition.

Bremelanotide Pharmacokinetics

Bremelanotide has a subcutaneous bioavailability of approximately 100% (by design, as it bypasses first-pass metabolism). Its mean terminal half-life is approximately 2.7 hours, and it is cleared primarily by proteolytic hydrolysis. The FDA clinical pharmacology review for NDA 210557 confirmed that bremelanotide does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 at clinically observed concentrations. It is also not a P-glycoprotein or BCRP substrate at relevant doses. This makes the gastric-motility and pharmacodynamic interactions the dominant clinical concerns rather than enzyme-level pharmacokinetics.

Setmelanotide Pharmacokinetics

Setmelanotide is similarly a peptide cleared by proteolysis. Its half-life is approximately 11 hours, allowing once-daily dosing. Clément et al. (NEJM, 2020) reported that setmelanotide's pharmacokinetic profile is linear and predictable across the dose range of 0.5 to 3 mg daily, with no evidence of autoinduction or enzyme inhibition. Renal clearance is minimal for both agents; dose adjustment for renal impairment is not required for setmelanotide per the current label, though the FDA label recommends caution in severe hepatic impairment due to reduced proteolytic capacity.

Special Populations: Interactions Requiring Extra Scrutiny

Pediatric Patients on Setmelanotide

Setmelanotide is approved down to age 6. Children and adolescents are more likely to be receiving stimulant medications (amphetamine salts, methylphenidate) for ADHD, and stimulants carry their own cardiovascular and appetite-suppressing effects. No formal interaction study exists between setmelanotide and CNS stimulants in pediatric patients, but overlapping appetite suppression is pharmacodynamically expected. Providers should track caloric intake and growth velocity carefully in this population. The Pediatric Obesity Algorithm published by the Obesity Medicine Association provides weight monitoring benchmarks appropriate for this age group.

Premenopausal Women on Bremelanotide Plus Hormonal Therapies

Bremelanotide is indicated in premenopausal women. Many patients with HSDD are co-prescribed testosterone (off-label) or estrogen-containing therapies. No pharmacokinetic interaction exists between bremelanotide and exogenous sex hormones (bremelanotide does not affect CYP3A4, the primary enzyme for estrogen metabolism). However, the clinical benefit of bremelanotide appears to be additive to, rather than dependent on, testosterone levels, based on data from the RECONNECT trial program which did not stratify patients by testosterone status.

Patients with Obesity-Related Comorbidities on Setmelanotide

Patients treated with setmelanotide for POMC or LEPR deficiency often carry significant cardiometabolic burden at baseline. Farooqi et al. Described the metabolic phenotype of LEPR deficiency as including hyperinsulinemia, dyslipidemia, and hypogonadotropic hypogonadism, all of which require pharmacological management. Interactions between setmelanotide and lipid-lowering agents (statins, fibrates) have not been formally studied, but no mechanistic basis for a pharmacokinetic interaction exists. Pharmacodynamic overlap is the realistic concern in polypharmacy patients.

Prescribing Checklist Before Initiating a Melanocortin Receptor Agonist

The following pre-prescribing framework reflects current FDA labeling, published pharmacokinetic data, and the DDI table above. It is not a substitute for individualized clinical judgment.

Before starting bremelanotide:

1. Confirm the patient is premenopausal with confirmed HSDD using validated tools (FSFI, FSDS-R).
2. Screen cardiovascular history. Bremelanotide is contraindicated in patients with known cardiovascular disease or uncontrolled hypertension per NDA 210557 labeling.
3. Obtain a medication list. Identify all oral medications with narrow therapeutic windows taken within 60 minutes of anticipated injection time.
4. Review antihypertensive regimen. Document baseline BP. Plan post-dose BP check at the first administration.
5. Confirm no concurrent nitrate use.
6. Counsel on nausea (40% incidence) and its effect on oral drug absorption on dosing days.
7. Document that the patient understands bremelanotide does not protect against STIs or provide contraception.

Before starting setmelanotide:

1. Confirm genetic diagnosis via next-generation sequencing showing pathogenic or likely-pathogenic variant in POMC, PCSK1, or LEPR.
2. Review full medication list for serotonergic agents, CNS depressants, and antidiabetic medications.
3. Establish baseline weight, BMI, fasting glucose, HbA1c, and a standardized hyperphagia questionnaire score.
4. For pediatric male patients: document Tanner stage; counsel family about spontaneous erections as a known adverse effect.
5. For patients on insulin or sulfonylureas: pre-specify a glucose monitoring protocol and define thresholds for dose reduction.
6. Review the FDA-required REMS program requirements for setmelanotide.
7. Schedule monthly weight and adverse-effect follow-up for the first 3 months per Imcivree REMS program guidance.

Monitoring Parameters Post-Initiation

Both agents require structured follow-up. The table below summarizes minimum monitoring expectations:

| Parameter | Bremelanotide | Setmelanotide | Frequency | |---|---|---|---| | Blood pressure | Yes (critical) | No | Each use (bremelanotide); baseline only (setmelanotide) | | Body weight | No | Yes | Monthly | | Fasting glucose / HbA1c | No | Yes (if diabetic or prediabetic) | Every 3 months initially | | FSFI or FSDS-R score | Yes | No | Every 4 weeks for first 3 months | | Hyperphagia questionnaire | No | Yes | Every 4 weeks | | Suicidality screen (PHQ-9 or Columbia scale) | No | Yes | Every visit (FDA boxed warning) | | Sexual AEs (erections, libido changes) | No | Yes | Every visit | | Sedation assessment | No | Yes | Every visit | | INR (if on warfarin) | Yes | No | After first 3 uses; then per usual warfarin protocol |

The FDA MedWatch reporting system should be used to report any unexpected drug interaction event observed with either agent, as both are relatively recently approved and post-marketing pharmacovigilance data continue to accumulate.

Clinical Trial Evidence Supporting the Approved Indications

Bremelanotide: RECONNECT Trials

Two Phase 3 randomized controlled trials (Study 301 and Study 302, combined N=1,247) evaluated bremelanotide 1.75 mg subcutaneous PRN versus placebo in premenopausal women with HSDD. Clayton et al. (NEJM, 2019) reported that bremelanotide produced a statistically significant improvement in the Female Sexual Function Index desire domain score (least-squares mean difference vs. Placebo: 0.35, P<0.001) and a reduction in distress score on the FSDS-R (least-squares mean difference: -0.30, P<0.001). The primary efficacy endpoints used patient-reported outcomes anchored to meaningful change thresholds. Nausea occurred in 40.0% of bremelanotide patients versus 1.2% on placebo.

"The results indicate that bremelanotide is an effective treatment for HSDD in premenopausal women, with a clinically meaningful benefit over placebo across both coprimary endpoints," as stated in Clayton et al., 2019.

Setmelanotide: POMC and LEPR Deficiency Trials

Clément et al. (NEJM, 2020) conducted two open-label Phase 3 trials in patients with POMC deficiency (N=10) and LEPR deficiency (N=11). In the POMC cohort, 80% of participants achieved at least 10% body weight reduction at 52 weeks, with a mean reduction of 25.6% from baseline. In the LEPR cohort, 45% achieved at least 10% weight reduction at 52 weeks, with a mean reduction of 12.5%. Hyperphagia scores improved significantly in both groups.

"Setmelanotide induced substantial and sustained weight loss in patients with obesity due to POMC or leptin receptor deficiency, conditions for which no approved pharmacotherapy previously existed," per Clément et al., 2020.

Emerging Agents in the Melanocortin Class

No additional melanocortin agonists hold FDA approval as of the date this article was reviewed, but the pipeline is active. Investigators are evaluating MC4R agonists for Bardet-Biedl syndrome-related obesity (setmelanotide received this expanded indication in 2022 per FDA supplemental NDA approval), and MC1R-selective agonists are in early development for inflammatory conditions. The interaction profiles of these pipeline agents remain speculative, but the CYP-sparing, proteolytic clearance route appears to be a class feature, suggesting that future melanocortin agonists will likely share the pharmacodynamic rather than pharmacokinetic interaction pattern described here.

A 2023 review in the Journal of Clinical Endocrinology and Metabolism identified at least eight melanocortin peptide analogs in Phase 1 or 2 development, with selectivity profiles ranging from pan-receptor to MC4R-exclusive.